Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
American Medical Systems
>
Endo Int'l (ENDP) Unit Receives FDA Warning Letter Tied to Form 483 Notice
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 5064068"]FDA warns Endo Health on AMS pelvic mesh plant</p><p><br /></p><p>April 17, 2014 by Brad Perriello</p><p><br /></p><p>The FDA sends a warning letter to Endo Health's American Medical Systems subsidiary over procedural violations at the Minnetonka, Minn., plant that makes pelvic mesh products.</p><p><br /></p><p>Endo Health Solutions (NSDQ:ENDP) said the FDA warned it about procedural violations at a Minnesota plant run by its American Medical Systems subsidiary that makes pelvic mesh products.</p><p><br /></p><p>The warning stems from an FDA inspection of the Minnetonka, Minn., plant in February that resulted in a "Form 483" warning from the watchdog agency, Endo Health said in a regulatory filing.</p><p><br /></p><p>"These observations, previously self-identified by AMS, were being addressed through a corrective action plan which AMS originally expected to complete beyond 2015," according to the filing.</p><p><br /></p><p>AMS accelerated and expanded its corrective action plan following the February inspection and receipt of the Form 483 warning, the company said. AMS management met in person with FDA representatives last month, according to the filing, when they "expanded further on the action plan and agreed on the approach."</p><p><br /></p><p>The agency's April 10 warning letter said "the corrective actions which AMS reviewed with the FDA on March 20, 2014, appear to be adequate," according to the filing, which noted that the FDA will require a follow-up inspection to validate the changes made at the plant.</p><p><br /></p><p>"AMS expects only limited related impact to its business at this time. The Minnetonka, Minnesota facility will continue to manufacture and ship products while AMS works with the FDA," according to the filing.</p><p><br /></p><p>Endo and a raft of other pelvic mesh makers are facing thousands of product liability lawsuits in state and federal court. Hundreds of cases involving Boston Scientific (NYSE:BSX), Johnson & Johnson (NYSE:JNJ), Secant Medical, C.R. Bard(NYSE:BCR), Endo Health Solutions (NSDQ:ENDP), Cook Medical and Coloplast (CPH:COLO B) have been consolidated into multi-district litigation under Judge Joseph Goodwin of the U.S. District Court for Southern West Virginia.</p><p><br /></p><p>In February, more cases were consolidated by Judge Arnold New, director of the Complex Litigation Center at the Philadelphia Court of Common Pleas. Earlier this week plaintiffs whose cases were removed to the U.S. District Court for Eastern Pennsylvania filed motions to have their suits moved to the court in Philly as well.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 5064068"]FDA warns Endo Health on AMS pelvic mesh plant April 17, 2014 by Brad Perriello The FDA sends a warning letter to Endo Health's American Medical Systems subsidiary over procedural violations at the Minnetonka, Minn., plant that makes pelvic mesh products. Endo Health Solutions (NSDQ:ENDP) said the FDA warned it about procedural violations at a Minnesota plant run by its American Medical Systems subsidiary that makes pelvic mesh products. The warning stems from an FDA inspection of the Minnetonka, Minn., plant in February that resulted in a "Form 483" warning from the watchdog agency, Endo Health said in a regulatory filing. "These observations, previously self-identified by AMS, were being addressed through a corrective action plan which AMS originally expected to complete beyond 2015," according to the filing. AMS accelerated and expanded its corrective action plan following the February inspection and receipt of the Form 483 warning, the company said. AMS management met in person with FDA representatives last month, according to the filing, when they "expanded further on the action plan and agreed on the approach." The agency's April 10 warning letter said "the corrective actions which AMS reviewed with the FDA on March 20, 2014, appear to be adequate," according to the filing, which noted that the FDA will require a follow-up inspection to validate the changes made at the plant. "AMS expects only limited related impact to its business at this time. The Minnetonka, Minnesota facility will continue to manufacture and ship products while AMS works with the FDA," according to the filing. Endo and a raft of other pelvic mesh makers are facing thousands of product liability lawsuits in state and federal court. Hundreds of cases involving Boston Scientific (NYSE:BSX), Johnson & Johnson (NYSE:JNJ), Secant Medical, C.R. Bard(NYSE:BCR), Endo Health Solutions (NSDQ:ENDP), Cook Medical and Coloplast (CPH:COLO B) have been consolidated into multi-district litigation under Judge Joseph Goodwin of the U.S. District Court for Southern West Virginia. In February, more cases were consolidated by Judge Arnold New, director of the Complex Litigation Center at the Philadelphia Court of Common Pleas. Earlier this week plaintiffs whose cases were removed to the U.S. District Court for Eastern Pennsylvania filed motions to have their suits moved to the court in Philly as well.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
American Medical Systems
>
Endo Int'l (ENDP) Unit Receives FDA Warning Letter Tied to Form 483 Notice
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
American Medical Systems
>
Endo Int'l (ENDP) Unit Receives FDA Warning Letter Tied to Form 483 Notice
>